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Abstract
Objectives. PsA is an inflammatory condition that can cause pain, fatigue, swelling and joint stiff-
ness. The consequences include impaired physical function, a high psychosocial burden, reduced qual-
ity of life and work disability. The presenting symptoms can be non-specific and varied, leading to
delays in diagnosis or referral to specialist teams. The aim of this study was to explore patients’ expe-
riences of being diagnosed and the initial management of PsA.
Methods. The study used a qualitative design, with data collected in one-to-one, face-to-face semi-
structured interviews.
Results. Fifteen newly diagnosed patients (<24 months) from three hospital sites in the southwest of
England participated. Interviews were transcribed, anonymized and analysed using inductive thematic
analysis. The following two main themes with sub-themes represent the data: symptom onset to spe-
cialist care: ‘it was the blind leading the blind’ (making sense of symptoms; mis-diagnosis and missed
opportunities; and fast and easy access to expertise); and diagnosis as a turning point: ‘having some-
body say you’ve got something wrong with you, I was euphoric’ (validation and reassurance; weighing
up treatment options; taking on self-management; and acknowledging loss and change).
Conclusion. Participants were already dealing with functional limitations and were highly distressed
and anxious by the time they received their diagnosis. Physical and mental outcomes could be im-
proved by the implementation of existing psoriasis management guidelines and strategies for earlier re-
ferral from primary care to rheumatology and by the development of guidelines on educational, self-
management and psychological support provision soon after diagnosis.
Key words: qualitative, diagnosis, psoriatic arthritis, rheumatology, specialist care, psychological distress,
self-management, treatment decisions.
Introduction
Psoriasis is a long-term, inflammatory skin condition
characterized by erythematous papules (skin lesions)
and plaques with overlying scale. A UK population-
based cohort study concluded that around 2.8% of the
general population have psoriasis [1]. PsA, an inflamma-
tory arthritis with an estimated prevalence in the UK of
Key Messages
. Implementation of existing psoriasis management guidelines could reduce delays from symptom onset to
rheumatology referral.
. At diagnosis, patients already experienced functional limitations, distress and anxiety.
. Educational and psychological support soon after diagnosis could help patients manage the impact and engage
with self-management.
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0.3–1.0% of the total population, is closely associated
with psoriasis. PsA affects men and women equally, and
its incidence peaks between the ages of 30 and
55 years [2]. It is a long-term condition, with flares of
disease activity and periods of remission. Symptoms
can include a red, scaly rash (psoriasis), swelling in the
fingers and toes (dactylitis), stiff and painful joints, thick-
ening and pitting of the nails, and fatigue. The impact of
symptoms includes limited physical function, reduced
quality of life and a high psychosocial burden [3]. On a
societal level, PsA is associated with significant health-
care costs, work disability and unemployment [4].
A systematic review and meta-analysis of observa-
tional and clinical studies estimated the prevalence of
PsA in patients with psoriasis to be one in four [5].
However, diagnosis is complex. Although psoriasis pre-
cedes the onset of PsA in 84% of patients, a small num-
ber will develop the rheumatic condition before
experiencing any skin symptoms, and some may never
develop skin symptoms [6]. There is no definitive test for
PsA. Diagnosis is usually made by rheumatologists
based on clinical expertise and a combination of a pro-
cess of elimination, medical history, physical examina-
tion, blood tests, MRI and X-rays of the affected joints.
The difficulty of diagnosis is important because the bur-
den of undiagnosed PsA is high, and there is emerging ev-
idence that delay in diagnosis results in worse outcomes
[7]. Even a 6 month delay from symptom onset to the first
visit to a rheumatologist contributes to the development of
peripheral joint erosions and worse long-term physical
function [8]. A systematic review and meta-analysis esti-
mated the prevalence of undiagnosed PsA to be 15.5%
[9]. Treatments for PsA have two main aims: to relieve
symptoms; and to slow the underlying progression of the
condition. Many pharmacological treatments are available
for the management of PsA, including MTX and other syn-
thetic and biological DMARDs [10]. Recent evidence sug-
gests that patients who undertake early ‘aggressive’
treatment, with more frequent assessment and escalation
in medication, can reach ‘low disease activity’ or even re-
mission (the absence of signs or symptoms of disease ac-
tivity) [11]. However, it is important to recognize that the
condition can be clinically mild, requiring minimal or no
pharmacological treatment.
The PROMPT programme (NIHR grant: RP-PG-1212-
20007) is investigating the clinical and cost benefits of
the early detection of PsA. The main study is a two-arm
parallel-group cluster randomized controlled trial of screen-
ing, using enhanced surveillance for PsA in primary care vs
standard care. The aim is to determine whether intervention
leads to earlier detection of undiagnosed PsA, which in turn
improves long-term outcomes for patients. Patients’ experi-
ences and views of the current health-care context are
likely to inform any implementation of a national screening
programme. Currently, the range of factors contributing to
delays in diagnosis are not well understood. They may in-
clude patient-related factors (e.g. reluctance to seek medi-
cal help with symptoms) and clinician-related factors (e.g.
the heterogeneous nature of PsA and lack of autoimmune
diagnostic markers, making diagnosis challenging) [12].
Evidence is needed of the patient journey from initial symp-
toms and interactions with health-care professionals,
through to diagnosis and early management of PsA. The
aim of this study was to gain insight into the experience of
obtaining a diagnosis of PsA and how this impacted the en-
gagement of patients with treatment and care.
Methods
Study design
A qualitative design was used because the study aimed
to explore patients’ experiences and views. Data
were collected using one-to-one, face-to-face, semi-
structured interviews. Semi-structured interviews can
generate insights into the thoughts, feelings and social
worlds of participants [13]. In the semi-structured for-
mat, participants are asked the same core questions,
but there is flexibility to probe more deeply and develop
new lines of enquiry based on responses. The core
questions in this study were based on an interview
schedule designed by the research team, comprising
patient research partners, rheumatology and nursing
clinicians and qualitative methodologists (see Table 1).
The study was approved by the Proportionate Review
Sub-committee of the North East – Newcastle & North
Tyneside 1 Ethics Committee (reference: 16/NE/0393)
and the Health and Applied Sciences Faculty Research
Ethics Committee of the University of the West of
England (reference: HAS.17.03.129).
Sampling and recruitment
Participants were sampled from three diverse secondary
care sites in the Southwest of England: a large, non-
specialist hospital; a small, non-specialist hospital; and
a specialist PsA centre. Recruitment was via two pro-
cesses: eligible patients were either given study informa-
tion by a research nurse, rheumatology consultant or
researcher when they attended a hospital outpatient
TABLE 1 Core interview questions
A: initial
symptoms
First symptoms noticed
What these symptoms indicated
Response to these symptoms
Time before seeking medical advice
B: interaction with
health-care
professionals
Reasons for contacting a health-care
professional/GP
Health-care professional/GP re-
sponse to symptoms
Referral to rheumatology
Initial interactions with rheumatology
Thoughts and feelings about
diagnosis
Views on health care/care pathways
C: post-diagnosis Treatment-related decisions
Impact of PsA and treatment
GP: general practitioners.
Emma Dures et al.
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clinic; or they received study information through the
post, based on the local clinical database. Patients were
eligible to take part if they were >18 years old, had re-
ceived a diagnosis of PsA confirmed by a rheumatology
consultant within the previous 24months, had enough
English language to participate in an interview and had
capacity to give informed consent.
Data collection
Interviews were conducted in non-clinical rooms at the sec-
ondary care site where the participant was under the care
of the rheumatology team. Before the start of the inter-
views, participants signed a consent form and provided de-
mographic data (age, sex, disease duration) and data on
current medications and disability (HAQ) [14].
Interviews were conducted by the lead author, who
had no prior relationship with the participants. Interviews
were audio-recorded, transcribed by a professional tran-
scription service, checked for accuracy against the origi-
nal audio files, and anonymized by changing the names
of people and places.
An inductive thematic analysis was conducted [15].
This approach was selected because it is appropriate
for research that is not based on pre-existing theory
about the phenomena being studied. It is suitable for
highlighting both similarities and differences across par-
ticipants [16]. This is important because we aimed to
capture variation in experiences of patients newly diag-
nosed with PsA. The lead author read all 15 transcripts
and coded chunks of text that related to the research
topic. Related clusters of coded text formed sub-
themes, which were grouped together to form a smaller
number of higher-order themes that described broad,
often abstract, elements in the dataset. A sub-set of six
anonymized transcripts were analysed independently by
four members of the study team (three patient research
partners and a clinical academic) to ensure that the find-
ings were informed by multiple viewpoints [17]. The final
analysis was based on the integrated interpretations of
these five team members.
Results
Fifteen patients participated in the study (10 women and
5 men). They ranged in age from 21 to 73 years and had
received a diagnosis of PsA between 1 and 24months
before taking part in the study (see Table 2).
Two main themes represent the data, and each theme
has three parts: the label; the theme summary; and the
sub-themes. Theme labels and sub-themes are listed in
Table 3. Data excerpts evidencing sub-themes are in
Tables 4 and 5.
TABLE 2 Demographic and clinical data
Gender Agea TDX Medications Flareb HAQc
M 51 6 MTX Y 2.625
M 72 6 MTX; folic acid NS 0.875
F 66 12 SSZ; paracetamol plus codeine Y 1.75
F 32 24 Zapain, SSZ; LEF, MTX Y 0.125
F 71 1 None Y 1.5
F 61 15 paracetamol; tramadol; omeprazole Y 2
F 48 3 MTX, zapain, ibuprofen N 1.5
F 53 4 MTX; folic acid Y 0.875
M 64 1 CSs; (due to start MTX þ folic acid) N 0.75
F 57 15 SSZ; MTX; prednisolone; naproxen; omeprazole N 1.5
F 21 16 Adcal – D3 N 0
M 55 NS None N 0
F 36 18 SSZ; omeprazole N 0.875
F 48 12 MTX; folic acid; fentbid forte gel Y 0
M 73 2 Voltarol N 0.125
aIn years.
bSelf-report of current active disease (N: no; NS: not sure; Y: yes).
cHeath Assessment Questionnaire: disability index of daily physical activities, with scores ranging from zero (without any
difficulty) to three (cannot be done at all).
TDX, time since diagnosis, in months.
TABLE 3 Labels of main themes and sub-themes
Main theme Sub-themes
1. From symptom onset
to specialist care: ‘it
was the blind leading
the blind’
Making sense of symptoms
Mis-diagnosis and missed
opportunities
Fast and easy access to
expertise
2. Diagnosis as a turning
point: ‘having some-
body say you’ve got
something wrong with
you, I was euphoric’
Validation and reassurance
Weighing up treatment options
Taking on self-management
Acknowledging loss and change
Diagnosis and initial management in PsA
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Theme 1: symptom onset to specialist care: ‘it was
the blind leading the blind’
The time taken to obtain a referral from primary to sec-
ondary care varied between participants. During this
period, participants and their general practitioners
(GPs) tried to make sense of intrusive and often per-
plexing symptoms. Participants who spent longer with
symptoms but without a diagnosis often struggled
more with the long-term emotional impact than those
who were referred to rheumatology departments after
only a few GP visits. This struggle was attributed to
high levels of pain, fatigue, the increasing impact of
symptoms on daily life, loss of confidence in health-
care professionals and high levels of anxiety about the
future (see Table 4).
Making sense of symptoms
Participants presented at GP consultations with symp-
toms such as stiffness, swelling, stinging, hot burning
sensations, and pain in their hands, wrists, ankles, feet
or knees. Often, it was an unacceptable level of pain
combined with an inability to carry out routine daily
tasks that prompted participants to see a GP.
Participants’ initial beliefs about the causes of the
symptoms included: over-doing a physical activity (e.g.
gardening or typing); psychological stress (e.g. owing to
TABLE 4 Data excerpts evidencing theme 1 sub-themes
Theme 1: symptom onset to specialist care: ‘it was the blind leading the blind’
(i) Making sense of symptoms
When my hands started swelling, yes that’s when I began to think maybe I should do something about it, because they were
getting quite painful and I was having more trouble doing things (F, 71 years old)
I’ve put my body through such a lot, and now it’s kicking me and telling me I’m getting my own back (M, 56 years old)
I wasn’t sure if it was stress related because I was going through a divorce at the time (F, 36 years old)
I think it was the blind leading the blind for a little bit. The doctor going ‘I don’t know’ and me going ‘well I don’t know’ (F, 32
years old)
I started mapping out a life plan of everything I did, my diet, what time I was getting up, absolutely everything, and I couldn’t
see a pattern, it didn’t seem to be linked to exercise or anything, it didn’t seem to flare up when I did more or less (M, 55
years old)
I did have three blood tests for RA with the doctor, so it wasn’t as though nothing was done (F, 61 years old)
Because I wasn’t getting anywhere fast, and because it had had such a massive impact on my lifestyle, I actually felt I didn’t
want to live (F, 48 years old)
Every day I’d wake up with a different joint, and I felt very depressed about it, very miserable, I stopped going out, I stopped
socializing, and I felt like I was becoming disabled (F, 36 years old)
I couldn’t hold a cup at one point, and to go from being perfectly alright, to being like that in a space of a couple of months, I
just wanted to kill myself, I really did (F, 48 years old)
(ii) Mis-diagnosis and missed opportunities
I went to the doctor [GP] and it was only in my, just above my thumb and they said it was RSI [repetitive strain injury] (F, 53
years old)
After examination and everything, he thought that I had OA (F, 66 years old)
. . . Oh you know, attention-seeking menopausal woman . . . I feel a bit cross really that they didn’t take it a bit more seriously,
because I think how much damage has been done while I haven’t been getting any treatment (F, 57 years old).
It was opportunities missed, because the more I read about the inflammation, the systemic inflammation, the more scared I
get, and I just want it under control (F, 48 years old)
A little bit angry, to be honest, that it wasn’t picked up for years, and possibly my fingers, which look deformed now, could
have been stopped (F, 53 years old)
Every time I’ve been to have my creams and stuff you need for the psoriasis, none of them have ever assessed me for PsA,
which they’re supposed to aren’t they, under the NICE guidelines, you’re supposed to be assessed every year (F, 48 years
old)
I did read something on the NHS website that if you have psoriasis the doctor’s surgery should check you for arthritis once
a year (F, 53 years old)
I remember going to the doctor and saying, because I have got psoriasis do you think it’s connected because I have got,
my nails are a bit ridged (F, 57 years old)
This type of arthritis is normally seen in somebody that would suffer with psoriasis. Now, I don’t, externally. My mum did
and my sister does, and my sister has gone on to have systemic lupus (F, 48 years old)
Well, I know my grandson has it [PsA], and we were all quite worried about it (M, 72 years old)
Members of my family do have PsA, so it was family history in the end (F, 21 years old)
(iii) Fast and easy access to expertise
I literally went from having a bit of a sore finger, saw a nurse, saw a doctor, went to the hospital, and it happened really
quickly, and I was really happy with it (F, 21 years old
I haven’t been messed about or anything, the original GP had said right I will do this for you, which he did . . . so, yeah, I think
it’s been really good. I have been treated well (M, 64)
F: female; GP: general practitioner; M: male.
Emma Dures et al.
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TABLE 5 Data excerpts evidencing theme 2 sub-themes
Theme 2: diagnosis as a turning point: ‘having somebody say you’ve got something wrong with you, I was euphoric’
(i) Validation and reassurance
Having somebody say, yeah, actually you’ve got something wrong with you, you are in trouble, and I was euphoric at get-
ting, being given a diagnosis (F, 57 years old)
Knowing what it was was definitely a big help to me and not knowing what it was was a source of great stress (F, 61 years
old)
When you see a specialist and someone deals with you, it is, it’s reassuring (M, 51 years old)
I feel they want to put a label on it. I’m not wholly in agreement they’ve got it right (M, 55 years old)
I do feel now I’ve got to a specialist department, I feel confident that they’re going to do their best for me, as long as I do my
bit and do my best myself (F, 57 years old)
Having this diagnosis hasn’t stopped the condition, yes, it’s opened up doors for treatment that hopefully will control it (F,
48 years old)
It’s [symptoms] still happening and they’ve upped the dosage to try and beat it, but I’ve got confidence at least it will, it
won’t be through the lack of trying anyway (M, 51 years old)
It’s the emotional support, it’s incredibly important. I think it would be quite easy just to go under with it, and just to end up
off work for weeks with depression, because it is depressing, because it affects everything (F, 36 years old)
It’s like, how could it go from my toe to taking MTX? It’s, yeah, it’s been very, very hard to get my head around. That’s what
I mean about the whole emotional and mental health side of things. There’s nobody there you can talk to about it, because
your doctor kind of like, ‘oh well it’s just monthly blood tests’ (F, 48 years old)
(ii) Weighing up treatment options
He [rheumatologist] said ‘it’s your decision whether you want to take strong medication or not’ and I said I’d rather not. It’s
not bothering me that much, and he seems to agree with my decision. He doesn’t think I’m being silly (M, 73 years old)
It’s been a discussion always, so I would do research, they have their own knowledge and own experience and then we’d
collaborate and make decisions together (F, 21 years old)
Everything was explained to me really well. I came in, like, not knowing a thing. I come out not an expert but understanding,
you know, what the problem was and stuff (M, 64 years old)
The fact that they are going to check liver and kidneys and things like that in blood tests makes it quite scary, because you
think obviously these side-effects could be quite, not dangerous, but serious (F, 71 years old)
I found it very difficult, so I thought, okay, I need to be in the right place to reduce my alcohol intake mentally and I then
need to decide if taking MTX is going to make me ill or not and is it worth it as I’ve lived with this so long already but I don’t
want it to get worse (F, 53 years old)
I wouldn’t get to the point where I was completely immobilized by it or let the disease damage the joints. I wouldn’t go that
far. I would prefer to control it with diet and exercise if there’s a way of doing that (M, 55 years old)
I was on MTX. It wasn’t doing an awful lot of good, so they upped the dose from 15 to 20 and then my liver started playing
up. My liver was not working, my hair started falling out, all that sort of thing, so they put me back down to 15, and then they
started me on, I can’t remember, LEF (F, 48 years old)
(iii) Taking on self-management
You can do something about it yourself, you know, as regards taking the medication and also doing the exercises, which
physio will tell you what to do (M, 72 years old)
There was a lot I found I could do, and I’ve lost a lot of weight in the last year. And that’s helped a lot as well. So, I think you
just sort of have to know what you can do yourself (F, 32 years old)
What I have found helpful, throughout all this, I have tried to meditate, and I was given a relaxation tape, which I do find very
helpful (F, 61 years old)
That particular appointment was a total waste of time and just left me feeling very depressed and guilty. It makes you feel
guilty, as if you’re doing something really wrong all the time (F, 66 years old)
(iv) Acknowledging loss and change
I had to pack up gardening for a start because I usually go to what I call gardening club on a Thursday, and that’s usually
quite physical work. I can’t grip, so I don’t go (M, 72 years old)
Still more time off work. Now it’s starting to impact me financially (F, 48 years old)
I do worry now that employers are not going to want to employ me (F, 21 years old)
I’ve got an elderly mother and I feel so guilty that I can’t help her with anything (F, 61 years old)
I am very worried about when it [baby] does arrive, what’s going to happen, I don’t want everything to fall on my partner.
He’s been incredibly supportive, but the fear is he will end up becoming my carer (F, 36 years old)
I have given up on the hope that my life will ever return to what it was because I feel that I’ve got to be realistic.. . . But if this
is as good as it gets then I need to make a life that’s worth living (F, 48 years old)
Once you’ve got it, you’ve basically just got to learn to live with it and control it and do your best really, just accept it. Some
things you can’t change (F, 66 years old)
I’m still really up and down with it. And there are times when I feel very bleak and depressed about it. And other times where
I’ve got more get up and go, and that’s usually when I’m in less pain and less tired (F, 36 years old)
F: female; M: male.
Diagnosis and initial management in PsA
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divorce, house renovations or work relocation); an inevi-
table aspect of ageing; consequences of childhood
physical activity (e.g. dance); acute sports injuries; and
body changes post-pregnancy or during the meno-
pause. These beliefs often contributed to an initial delay
in contacting a health-care professional, because partic-
ipants thought the symptoms would resolve without in-
tervention. For some, symptoms seemed to come and
go at random, resolving on their own only to flare up
again sometime later. Participants looked for patterns
related to their daily activities, diet and exercise, but
were still unable to work out what was happening and
why. Often, GPs also found it difficult to make sense of
symptoms and piece together what was happening.
This difficulty was compounded in some cases where a
blood test came back as ‘normal’.
Over time, the experience of worsening, debilitating
symptoms and not knowing why took an immense psy-
chological toll. Participants described a life increasingly
dominated by anxiety, pain and restriction. For some,
the impact was overwhelming to the point of passive
suicide ideation (expression of a wish to die, but without
specific plans to commit suicide) during the interviews.
Mis-diagnosis and missed opportunities
Many participants reported multiple visits to health-care
professionals, usually GPs, over a period of years before
they received their diagnosis of PsA. During this time,
there were often mis-diagnoses, which delayed referral to
rheumatology, including repetitive strain injury, OA and
Morton’s neuroma. This protracted journey could erode
the confidence of participants in health-care professionals
and the health-care system. The negative views of partici-
pants about the time spent seeking answers in primary
care were compounded when they perceived that GPs
had been dismissive or disbelieving, and they had sus-
tained unnecessary joint damage as a result.
Participants acknowledged that GPs could not be
expected to have specialist knowledge about PsA.
However, they often believed that there had been
missed opportunities at various points in the health-care
system. This was particularly the case for patients with
psoriasis who were under the care of dermatology
teams. Subsequent to their PsA diagnosis, participants
became aware that health-care professionals had not
adhered to National Institute for Health and Care
Excellence (NICE) guidelines for assessment of patients
with psoriasis for PsA. Almost every participant
explained that a family member had either psoriasis, an
inflammatory rheumatic condition or both. For many,
symptoms started to make sense and a diagnosis was
reached when health-care professionals asked about
family members.
Fast and easy access to expertise
Circuitous journeys to diagnosis contrasted with those
participants who described fast and efficient GP refer-
rals to rheumatology. As a result, these participants felt
comparatively safe and supported, and satisfied with
their health care.
Theme 2: diagnosis as a turning point: ‘having
somebody say you’ve got something wrong with
you, I was euphoric’
Getting a diagnosis was a psychological and practical
turning point for participants. This related to being be-
lieved and reassured by health-care professionals with
the relevant expertise and coming to understand that
their symptoms were attributable to a manageable long-
term condition. The diagnosis enabled participants to
act, such as starting treatments, and to make psycho-
logical adjustments, such re-evaluating their expecta-
tions for the future. However, for some the initial relief
was short lived. Their sense that physical and psycho-
logical damage had already been done made them fear-
ful for their long-term health. Despite engaging with their
health care and making helpful lifestyle changes, some
participants continued to experience high levels of emo-
tional distress (see Table 5).
Validation and reassurance
After the route to diagnosis had been drawn out and
participants had felt dismissed or discredited, diagnosis
was experienced initially as a relief and a form of
validation. It made sense to participants, except for one
patient who wondered whether it reflected health-care
professionals’ wish to assign a label, rather than cer-
tainty about PsA. Diagnosis also brought the possibility
of managing the condition. Specialist medical expertise
was a valued source of practical support, making partic-
ipants feel confident and hopeful about symptom
improvement.
However, the relief at diagnosis could be short lived,
because the condition and its treatment continued to
impact participants’ daily lives. A lack of emotional sup-
port influenced the ways in which participants coped
with their PsA, with several reporting low mood, depres-
sion and anxiety. They discussed how they would like to
access resources to address these feelings. This was an
aspect of care that was identified as lacking.
Weighing up treatment options
Diagnosis led to decisions about treatments and behaviou-
ral changes to manage the impact of PsA. Communication
with the rheumatology team was a key factor in how par-
ticipants worked through their mixed feelings about under-
taking treatment. Participants often reported a process of
shared decision-making with the clinical team, underpinned
by good provision of information. Discussions about phar-
macological treatments could alarm participants; for exam-
ple, the association of MTX with cancer treatments and the
need for blood monitoring. However, the possibility of
long-term disability and joint damage was also a worry and
influenced participants’ treatment decisions. At the time of
the present study, some in this group of newly
diagnosed participants were still struggling to find a treat-
ment regimen that could help with their symptoms and
control their PsA.
Emma Dures et al.
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Taking on self-management
Alongside the medical management, participants dis-
cussed the importance of doing what they could to help
themselves keep well. This included a range of behav-
iours to minimize or reduce the impact of PsA, such as
exercising joints, pacing activity, relaxation techniques,
weight loss, reducing alcohol intake with MTX, and
keeping physically active. However, supporting self-
management and lifestyle changes, such as smoking
cessation, required health-care professionals to work
with the patient, and to understand their priorities and
resources at that point and to avoid blame or criticism
that might cause upset or resistance.
Acknowledging loss and change
Participants reported multiple losses, including valued
activities and their sense of pre-symptom onset identity.
Some participants were coming to terms with financial
losses and worries about prospects for paid work. There
was upset and worry about not being able to fulfil im-
portant roles, such as caring for others, and the impact
of this on other people. Accepting a future with PsA was
described as challenging and an on-going process that
takes time. For some participants, the emotional and
psychological impact of PsA remained a continual
challenge.
Discussion
These findings have identified challenges and opportuni-
ties for intervention from symptom onset to treatment
and care by rheumatology teams. Although participants
acknowledged the difficulties facing GPs owing to the
disparate and perplexing presentation of their symptoms,
they also reported examples of being dismissed or disbe-
lieved, and how the impact that symptoms were having
on their psychological well-being was overlooked. Often,
they were not asked about a family history of skin and
rheumatic conditions, which was a key indication that
their symptoms could be attributable to PsA. In addition,
some participants reported a failure to adhere to NICE
guidelines on the management of psoriasis (Clinical
guideline CG153, updated in 2017 [18]. The guidance on
assessment and referral states that people with any type
of psoriasis should be assessed for PsA (Section
1.2.1.1)). One potential route to implementation of an ed-
ucational or public health intervention for earlier diagnosis
could be through the community pharmacy, with staff of-
fering screening and information [19].
Diagnosis was a turning point for participants, often
bringing relief and a sense of validation. PsA can vary in
clinical severity, and how this was communicated in dis-
cussions about treatment options was important.
Discussions between patients and members of the rheu-
matology team about whether to start medication and
how to support self-management highlight that the need
for an early diagnosis goes beyond the medical model.
It includes the psychological need for an explanation
and reassurance, sometimes after years of living with
symptoms but with no diagnosis or effective treatment.
By this point, several participants were highly distressed
and anxious. This has implications for patients’ physical
and mental outcomes. There is a well-established body of
evidence from inflammatory rheumatic conditions, such
as RA, that the impact of negative affective states is far
reaching; this includes poor treatment outcomes, poor ad-
herence to medications, high levels of pain and fatigue,
and poor social and sexual function [20–23]. There is less
research available on psychological status specifically in
patients with PsA, but emerging evidence suggests that
psychological distress remains an issue long after the pe-
riod around diagnosis. A qualitative interview study with
24 patients between 4months and 29years post-PsA di-
agnosis reported that suicidal ideation was commonly
expressed [24]. Participants’ psychological struggles were
attributed to fears about long-term physical deterioration
and the strain of hiding their distress from other people,
who they perceived as dismissive and belittling. Illness
beliefs have been identified as an important factor in
shaping patients’ responses to their PsA and the subse-
quent impact of living with the condition. In a sample of
179 patients with PsA, hierarchical multiple regression
models indicated that negative beliefs about the conse-
quences of PsA and behavioural disengagement as a
coping method predicted levels of depression, after con-
trolling for the severity of the condition [25]. The role of ill-
ness beliefs was further supported in a secondary
analysis of data collected in eight focus groups with 41
participants with PsA [26]. In addition, the authors
highlighted the influence of uncertainty about the condi-
tion and its management on how patients engaged with
treatment-related decisions.
Taken together with findings from the present study,
there is a strong argument for addressing the illness
beliefs and coping strategies of newly diagnosed patients,
an aspect of care that participants identified as missing.
Support should include exploration of expectations about
long-term outcomes and treatment efficacy. There is evi-
dence that attention should be given to ‘illness uncer-
tainty’, which can be defined as the inability to determine
the meaning of illness-related events, shaped by ambigu-
ity about the condition, complexity in relationship to treat-
ment and the health-care system, lack of information
about diagnosis or severity, and the unpredictability of the
prognosis [27]. This uncertainly can be experienced as a
cognitive stressor, a sense of loss of control, and a per-
ceptual state of doubt, and has been associated with diffi-
culties in adjusting and unhelpful coping styles [28].
The present study supports recent research looking at
outcomes important to patients when designing and
evaluating care pathways. Treatment of PsA is challeng-
ing because several health domains can be involved. In
current clinical practice, flare is a measure of swollen or
tender joint counts. However, a qualitative study found
that social withdrawal, psychological symptoms, fatigue
and loss of function were also significant features for
patients [29]. A focus group study investigating
Diagnosis and initial management in PsA
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treatment outcomes found that in addition to symptom
alleviation, patients valued a reduction of disease im-
pact, improved prognosis, and the minimization of treat-
ment harm and burden [30]. Incorporating the
assessment of these outcomes in clinical practice might
facilitate discussions between patients and rheumatol-
ogy teams and enhance patient well-being.
Strengths and limitations
A strength of this study is that participants were reflecting
on their experiences of diagnosis within the first 2 years,
and in the current health-care system. Participants of a
wide age range of took part, from 21 to 73years old, with
a range of PsA severity. Their data were analysed by
team members with different backgrounds, including pa-
tient partners with first-hand experience of living with
PsA, and academics and methodologists who work in
rheumatology settings. A study limitation is that although
the sample were recruited from three diverse sites, the
experiences of participants were of health-care provision
in the Southwest of England. In addition, future research
should investigate the impact of gender and ethnicity on
experiences of diagnosis and early management in PsA.
Conclusions
The process from symptom onset to diagnosis was of-
ten difficult and drawn out, with participants and GPs
unable to make sense of presenting symptoms. It seems
likely that referral to rheumatology was delayed because
questions were not asked about skin and rheumatic
conditions among family members, and psoriasis man-
agement guidelines were not adhered to. Receiving a di-
agnosis could bring relief and was a practical and
psychological turning point for some participants. The
knowledge that they had PsA enabled them to consider
treatment-related decisions and engage with a range of
self-management behaviours. However, by this point
many participants were also dealing with functional limi-
tations and were highly distressed and anxious. A key
feature of their distress related to uncertainty and fear-
fulness about the long-term impact of the condition.
Care pathways could be enhanced by: implementation
of existing psoriasis management guidelines and strate-
gies to facilitate earlier referral from primary care to
rheumatology; the development and implementation of
guidelines for educational and self-management support
at the point of diagnosis; psychological support provi-
sion for patients experiencing distress and anxiety to
develop helpful coping strategies; and the evaluation of
outcomes important to patients in care pathways.
Basing treatment and care on such a biopsychosocial
model has the potential to improve physical and mental
outcomes for patients.
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